Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Analytical Chemistry (1)
- Biochemistry (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Biological Factors (1)
- Biophysics (1)
-
- Carbohydrates (1)
- Cardiovascular Diseases (1)
- Chemistry (1)
- Diseases (1)
- Heterocyclic Compounds (1)
- Life Sciences (1)
- Medical Specialties (1)
- Medicinal and Pharmaceutical Chemistry (1)
- Medicinal-Pharmaceutical Chemistry (1)
- Oncology (1)
- Organic Chemicals (1)
- Organic Chemistry (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Physical Chemistry (1)
- Physical Sciences and Mathematics (1)
- Structural Biology (1)
- Translational Medical Research (1)
Articles 1 - 2 of 2
Full-Text Articles in Enzymes and Coenzymes
Understanding And Targeting The C-Terminal Binding Protein (Ctbp) Substrate-Binding Domain For Cancer Therapeutic Development, Benjamin L. Morris
Understanding And Targeting The C-Terminal Binding Protein (Ctbp) Substrate-Binding Domain For Cancer Therapeutic Development, Benjamin L. Morris
Theses and Dissertations
Cancer involves the dysregulated proliferation and growth of cells throughout the body. C-terminal binding proteins (CtBP) 1 and 2 are transcriptional co-regulators upregulated in several cancers, including breast, colorectal, and ovarian tumors. CtBPs drive oncogenic properties, including migration, invasion, proliferation, and survival, in part through repression of tumor suppressor genes. CtBPs encode an intrinsic dehydrogenase activity, utilizing intracellular NADH concentrations and the substrate 4-methylthio-2-oxobutyric acid (MTOB), to regulate the recruitment of transcriptional regulatory complexes. High levels of MTOB inhibit CtBP dehydrogenase function and induce cytotoxicity among cancer cells in a CtBP-dependent manner. While encouraging, a good therapeutic would utilize >100-fold …
Probing Allosteric, Partial Inhibition Of Thrombin Using Novel Anticoagulants, Stephen S. Verespy Iii
Probing Allosteric, Partial Inhibition Of Thrombin Using Novel Anticoagulants, Stephen S. Verespy Iii
Theses and Dissertations
Thrombin is the key protease that regulates hemostasis; the delicate balance between procoagulation and anticoagulation of blood. In clotting disorders, like deep vein thrombosis or pulmonary embolism, procoagulation is up-regulated, but propagation of clotting can be inhibited with drugs targeting the proteases involved, like thrombin. Such drugs however, have serious side effects (e.g., excessive bleeding) and some require monitoring during the course of treatment. The reason for these side effects is the mechanism by which the drugs’ act. The two major mechanisms are direct orthosteric and indirect allosteric inhibition, which will completely abolish the protease’s activity. Herein we sought an …